This announcement includes the rate for the abbreviated new drug application, prior approval supplement to an approved ANDA, drug master file, active pharmaceutical ingredient facilities and finished dosage form facilities user fees.
GDUFA authorizes FDA to assess and collect user fees for certain applications and supplements for human generic drug products, on certain generic FDF and API facilities, and on Type-II active pharmaceutical ingredient DMFs to be made available for reference for generic applications.
These fees are effective on Oct.1, 2014, and will remain in effect through Sept. 30, 2015.